Search and filter

The French government has presented a restrictive 2026 Social Security Financing Bill featuring €5 billion in total healthcare savings and a significant overhaul of pharmaceutical pricing and taxation mechanisms.

The French pricing body has reported nearly €8 billion in rebates and over €850 million in price cuts for the 2024 calendar year.

A new proposal by Germany’s health quality institute suggests pharmaceutical companies should pay a 1 per cent turnover tax to sustain the nation’s medical register infrastructure.

A sharp reduction in the 2026 repayment rate for branded medicines marks a turning point for the UK’s voluntary pricing agreement, easing the financial burden on developers of innovative therapies.

Italy has abolished a decade-old mechanism that allowed pharmaceutical firms to avoid mandatory price reductions, signalling a more rigid approach to public healthcare expenditure and impacting international reference prices

New legislative measures in Italy have introduced structural price reductions for reimbursed medicines and established stricter renegotiation protocols for biological products.

Pharmaceutical manufacturers in Italy are facing a more intricate year-end financial reconciliation as the national regulator integrates a new rebate mechanism into the standard retail payback cycle.

Pharmaceutical companies in Italy must now verify their medicine sales records to ensure the accurate calculation of the retail pharmacy payback for the first half of 2025.

The Scottish Medicines Consortium has modernised the standard contractual terms for pricing agreements, clarifying the legal obligations for health boards and suppliers across NHS Scotland.

Pharmaceutical companies now have an extra month to decide on their participation in the 2026 voluntary pricing scheme, giving them more time to weigh its financial implications against the less predictable Statutory Scheme.